NKG2A is a marker for acquisition of regulatory function by human CD8+ T cells activated with anti-CD3 antibody

European Journal of Immunology

Volumn 41, Issue 7, 2011, Pages 1832-1842

  Ablamunits, Vitaly ^a   Henegariu, Octavian ^a   Preston Hurlburt, Paula ^a   Herold, Kevan C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti CD3 mAb; CD8; Immune therapy; Treg

Indexed keywords

CD94 ANTIGEN; CELL DIVISION CYCLE 20 HOMOLOG; CYTOCHROME P450 1B1; ECTONUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 1; EUKARYOTIC TRANSLATION INITIATION FACTOR 1A; INTERFERON INDUCED PROTEIN 44; INTERFERON INDUCED PROTEIN 44 LIKE; INTERLEUKIN 2 RECEPTOR ALPHA; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY C; NATURAL KILLER CELL RECEPTOR NKG2A; PROTEIN; TEPLIZUMAB; THIOSULFATE SULFURTRANSFERASE; UBIQUITIN CONJUGATING ENZYME E2; UNCLASSIFIED DRUG; XIAP ASSOCIATED FACTOR 1;

ARTICLE; CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; BIOLOGICAL MARKERS; CD8-POSITIVE T-LYMPHOCYTES; GENE EXPRESSION; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; MICROARRAY ANALYSIS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY C; POLYMERASE CHAIN REACTION; PROTEIN ISOFORMS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; T-LYMPHOCYTES, REGULATORY;

EID: 79959716366     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201041258     Document Type: Article

References (33)

1. Herold, K. C., Gitelman, S. E., Masharani, U., Hagopian, W., Bisikirska, B., Donaldson, D., Rother, K. et al., A single course of anti-CD3 monoclonal antibody hOKT3{gamma}1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005. 54: 1763-1769.
2. Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E. et al., Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 2002. 346: 1692-1698.
3. Bisikirska, B., Colgan, J., Luban, J., Bluestone, J. A. and Herold, K. C., TCR stimulation with modified anti-CD3 mAb expands CD8 T cell population and induces CD8CD25 Tregs. J. Clin. Invest. 2005. 115: 2904-2913.
4. Ablamunits, V., Bisikirska, B. and Herold, K. C., Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF. Eur. J. Immunol. 2010. 40: 2891-2901.
5. Herold, K. C., Burton, J. B., Francois, F., Poumian-Ruiz, E., Glandt, M. and Bluestone, J. A., Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J. Clin. Invest. 2003. 111: 409-418.
6. Brooks, A. G., Posch, P. E., Scorzelli, C. J., Borrego, F. and Coligan, J. E., NKG2A complexed with CD94 defines a novel inhibitory natural killer cell receptor. J. Exp. Med. 1997. 185: 795-800.
7. Culley, F. J., Johnson, M., Evans, J. H., Kumar, S., Crilly, R., Casasbuenas, J. and Schnyder, T., Natural killer cell signal integration balances synapse symmetry and migration. PLoS Biol. 2009. 7: e1000159.
8. Ablamunits, V., Bisikirska, B. C. and Herold, K. C., Human regulatory CD8 T cells. Ann. N. Y. Acad. Sci. 2008. 1150: 234-238.
9. Lazetic, S., Chang, C., Houchins, J. P., Lanier, L. L. and Phillips, J. H., Human natural killer cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits. J. Immunol. 1996. 157: 4741-4745.
10. Houchins, J. P., Yabe, T., McSherry, C. and Bach, F. H., DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. J. Exp. Med. 1991. 173: 1017-1020.
11. Posch, P. E., Borrego, F., Brooks, A. G. and Coligan, J. E., HLA-E is the ligand for the natural killer cell CD94/NKG2 receptors. J. Biomed. Sci. 1998. 5: 321-331.
12. Miller, J. D., Weber, D. A., Ibegbu, C., Pohl, J., Altman, J. D. and Jensen, P. E., Analysis of HLA-E peptide-binding specificity and contact residues in bound peptide required for recognition by CD94/NKG2. J. Immunol. 2003. 171: 1369-1375.
13. Borrego, F., Kabat, J., Sanni, T. B. and Coligan, J. E., NK cell CD94/NKG2A inhibitory receptors are internalized and recycle independently of inhibitory signaling processes. J. Immunol. 2002. 169: 6102-6111.
14. Kabat, J., Borrego, F., Brooks, A. and Coligan, J. E., Role that each NKG2A immunoreceptor tyrosine-based inhibitory motif plays in mediating the human CD94/NKG2A inhibitory signal. J. Immunol. 2002. 169: 1948-1958.
15. Billerbeck, E., Blum, H. E. and Thimme, R., Parallel expansion of human virus-specific FoxP3- effector memory and de novo-generated FoxP3+ regulatory CD8+ T cells upon antigen recognition in vitro. J. Immunol. 2007. 179: 1039-1048.
16. Billerbeck, E., Bottler, T. and Thimme, R., Regulatory T cells in viral hepatitis. World J. Gastroenterol. 2007. 13: 4858-4864.
17. + T cells in chronic hepatitis C virus infection. J. Gen. Virol. 2009. 90: 1692-1701.
18. Billerbeck, E. and Thimme, R., CD8+ regulatory T cells in persistent human viral infections. Hum. Immunol. 2008. 69: 771-775.
19. + regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4. Proc. Natl. Acad. Sci. USA 2007. 104: 8029-8034.
20. + regulatory T cells in multiple sclerosis. J. Neuroimmunol. 2008. 195: 121-134.
21. Panoutsakopoulou, V., Huster, K. M., McCarty, N., Feinberg, E., Wang, R., Wucherpfennig, K. W. and Cantor, H., Suppression of autoimmune disease after vaccination with autoreactive T cells that express Qa-1 peptide complexes. J. Clin. Invest. 2004. 113: 1218-1224.
22. + regulatory T cells: interruption of the NKG2A-Qa-1 interaction allows robust suppressive activity and resolution of autoimmune disease. Proc. Natl. Acad. Sci. USA 2008. 105: 19420-19425.
23. Leavenworth, J. W., Schellack, C., Kim, H. J., Lu, L., Spee, P. and Cantor, H., Analysis of the cellular mechanism underlying inhibition of EAE after treatment with anti-NKG2A F(ab')2. Proc. Natl. Acad. Sci. USA 2010. 107: 2562-2567.
24. + immunoregulatory T cells that control autoimmune diabetes. Immunity 2000. 12: 431-440.
25. Bennett, C. L., Christie, J., Ramsdell, F., Brunkow, M. E., Ferguson, P. J., Whitesell, L., Kelly, T. E. et al., The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 2001. 27: 20-21.
26. + regulatory T cells: thymus or periphery. J. Clin. Invest. 2003. 112: 1310-1312.
27. Wildin, R. S., Ramsdell, F., Peake, J., Faravelli, F., Casanova, J. L., Buist, N., Levy-Lahad, E. et al., X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. 2001. 27: 18-20.
28. + regulatory T lymphocytes. Int. Immunol. 2006. 18: 1509-1519.
29. + Treg in SLE patients: a heritable trait associated with CTLA4 and TGFbeta gene variants. BMC Immunol. 2009. 10: 5.
30. Shum, B. P., Flodin, L. R., Muir, D. G., Rajalingam, R., Khakoo, S. I., Cleland, S., Guethlein, L. A. et al., Conservation and variation in human and common chimpanzee CD94 and NKG2 genes. J. Immunol. 2002. 168: 240-252.
31. Ricciardelli, I., Lindley, K. J., Londei, M. and Quaratino, S., Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease. Immunology 2008. 125: 178-183.
32. Xu, D., Alegre, M. L., Varga, S. S., Rothermel, A. L., Collins, A. M., Pulito, V. L., Hanna, L. S. et al., In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol. 2000. 200: 16-26.
33. Park, K. S., Park, J. H. and Song, Y. W., Inhibitory NKG2A and activating NKG2D and NKG2C natural killer cell receptor genes: susceptibility for rheumatoid arthritis. Tissue Antigens 2008. 72: 342-346.